Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05277402 · ClinicalTrials.gov registry record · Phase 1
ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
A Phase 1 study, sponsored by Adagene.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT05277402 is a Phase 1 study that has completed, run by Adagene. The registered enrollment target is 6 participants.
The verdict
NCT05277402, a Phase 1 study, has completed, sponsored by Adagene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a Phase 1b, open-label, dose escalation study to evaluate the safety, tolerability, PK, and immunogenicity of an ADG116-pembrolizumab combination regimen in patients with advanced/metastatic solid tumors. Study drug ADG116, is an anti -CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4. Pembrolizumab is a PD-1 receptor-blocking antibody (a humanized IgG4 monoclonal antibody) which is indicated for the treatment of patients across a number of indications. The treatment strategy of using anti-PD 1 therapy combined with anti-CTLA-4 therapy is to explore the potential of combination checkpoint inhibition regimens for the enhanced antitumor efficacy results.
Interventions
- DRUG ADG116
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-02-09 |
| Est. Completion | 2022-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05277402
The ClinicalTrials.gov registry entry for NCT05277402 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Adagene, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ADG116 is the first listed.
NCT05277402 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05277402 about?
NCT05277402 is a clinical study titled "ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors". This is a Phase 1b, open-label, dose escalation study to evaluate the safety, tolerability, PK, and immunogenicity of an ADG116-pembrolizumab combination regimen in patients with advanced/metastatic solid tumors. Study drug ADG116, is an anti -CTLA-4 fully human monoclonal antibody that specifically...
What is the current status of trial NCT05277402?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2022-02-09. Estimated completion is 2022-12-01.
What interventions are being tested in trial NCT05277402?
The interventions under investigation include: ADG116 (DRUG).
Who is sponsoring clinical trial NCT05277402?
This trial is sponsored by Adagene, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.